Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma

[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory]
Tom Werner

* The U.S. Food and Drug Administration has granted Atossa Therapeutics’ (ATOS) treatment for soft tissue sarcoma orphan drug designation, offering potential support for the development of this rare cancer therapy.
* Atossa Therapeutics’ (ATOS) shares rose over 13% to $0.66 in premarket trading.
* Source [https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1119225]

 

MORE ON ATOSSA THERAPEUTICS

* Seeking Alpha’s Quant Rating on Atossa Therapeutics [https://seekingalpha.com/symbol/ATOS/ratings/quant-ratings]
* Historical earnings data for Atossa Therapeutics [https://seekingalpha.com/symbol/ATOS/earnings]
* Financial information for Atossa Therapeutics [https://seekingalpha.com/symbol/ATOS/income-statement]